GNH USA

Europe — EMA

Menquadfi

GNH USA supplies Menquadfi (Neisseria meningitidis serogroup C), a vaccine for prevention of invasive meningococcal disease caused by serogroup C.

Neisseria Meningitidis, Serogroup C, Polysaccharide, Conjugated To Tetanus Toxoid, Neisseria Meningi

Request sourcing

1
Pack/s

What is Neisseria Meningitidis, Serogroup C, Polysaccharide, Conjugated To Tetanus Toxoid, Neisseria Meningi?

Neisseria meningitidis serogroup C polysaccharide conjugated to tetanus toxoid, the active ingredient in Menquadfi, is a vaccine presented as an injectable solution for intramuscular use. It is used to prevent invasive disease caused by Neisseria meningitidis serogroup C, primarily in individuals at risk such as adolescents, travelers to endemic areas, and certain high‑risk groups.

GNH USA supplies Menquadfi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and health‑care providers worldwide across multiple continents.

What is Neisseria Meningitidis, Serogroup C, Polysaccharide, Conjugated To Tetanus Toxoid, Neisseria Meningi used for?

Menquadfi is a conjugate vaccine that targets Neisseria meningitidis serogroup C to prevent meningococcal disease. - Invasive meningococcal disease (serogroup C): provides active immunity to prevent infection caused by the serogroup C capsule. - Travel to endemic regions (serogroup C): reduces the risk of acquiring meningococcal disease during travel. - Outbreak control (serogroup C): helps limit spread of serogroup C disease in affected populations.

What are the side effects of Neisseria Meningitidis, Serogroup C, Polysaccharide, Conjugated To Tetanus Toxoid, Neisseria Meningi?

Menquadfi, like other injectable vaccines, may be associated with local and systemic reactions after administration.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or swelling: localized erythema or edema around the injection area. - Fever: transient low‑grade temperature rise within 24‑48 hours. - Headache or fatigue: mild systemic symptoms that resolve spontaneously.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Guillain‑Barré syndrome: rare neurological disorder reported post‑vaccination. - Seizures: infrequent occurrence, especially in children with fever.

What precautions apply to Neisseria Meningitidis, Serogroup C, Polysaccharide, Conjugated To Tetanus Toxoid, Neisseria Meningi?

Before administering Menquadfi, consider the following precautions to ensure safe and effective use. - Allergy screening: avoid use in individuals with known hypersensitivity to tetanus toxoid or any vaccine component. - Acute illness: postpone vaccination in persons with moderate or severe febrile illness until recovery. - Immunocompromised patients: vaccine may elicit a reduced immune response; assess benefit‑risk. - Pregnancy and lactation: consult a healthcare professional to weigh potential risks and benefits. - Concurrent vaccines: follow recommended intervals when co‑administering with other immunizations. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

What does Neisseria Meningitidis, Serogroup C, Polysaccharide, Conjugated To Tetanus Toxoid, Neisseria Meningi interact with?

Vaccines can interact with other agents that affect immune response or cause overlapping adverse events.

Major Interactions (Avoid): - Live vaccines administered within 4 weeks: may interfere with immune response; separate administrations. - Immunoglobulin or blood products given within 3 months: can neutralize vaccine antigens and diminish effectiveness.

Moderate Interactions (Monitor Closely): - Antipyretic prophylaxis (e.g., acetaminophen, ibuprofen): may modestly reduce antibody titers if taken before vaccination. - Immunosuppressive therapy: may lower vaccine‑induced immunity; monitor serologic response. - Antibiotics for acute infection: generally safe but assess timing relative to vaccination.

Frequently asked questions

What is Menquadfi used for?+
Menquadfi is a conjugate vaccine indicated for the prevention of invasive disease caused by Neisseria meningitidis serogroup C. It is administered to individuals at risk, such as adolescents, travelers to endemic regions, and populations in outbreak settings, to stimulate protective immunity against serogroup C meningococcal infection.
How does Neisseria meningitidis serogroup C conjugate vaccine work?+
The vaccine contains capsular polysaccharide from serogroup C linked to tetanus toxoid, converting the polysaccharide into a T‑cell‑dependent antigen. This conjugation activates helper T cells, leading to strong B‑cell responses and the production of high‑affinity anti‑capsular antibodies that neutralize the bacteria and prevent invasive disease.
What is the usual dose of Menquadfi?+
The dose of Menquadfi is determined by the prescribing healthcare professional based on age, risk factors and local immunization schedules. Typically a single intramuscular injection is given, with possible booster doses as recommended by public‑health authorities. Exact dosing and timing should be confirmed with the prescriber.
Is Menquadfi safe to use during pregnancy or breastfeeding?+
Safety data for Menquadfi in pregnancy are limited, and the vaccine should only be administered after a risk‑benefit assessment by a qualified healthcare provider. Breastfeeding is not a contraindication, but mothers should discuss any concerns with their clinician to ensure appropriate protection for both mother and infant.
How do I order Menquadfi from GNH USA?+
To place an order, submit an enquiry on the Menquadfi product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and any necessary import documentation.
How does Menquadfi compare with other meningococcal vaccines?+
Menquadfi is a serogroup C conjugate vaccine, offering T‑cell‑dependent immunity and long‑lasting protection, whereas polysaccharide‑only vaccines may induce a shorter‑duration response and are less effective in young children. Compared with quadrivalent conjugate vaccines that cover serogroups A, C, W and Y, Menquadfi targets only serogroup C, making it suitable for regions where that serogroup predominates.
How should Menquadfi be stored and handled?+
Menquadfi must be stored refrigerated at 2 °C to 8 °C. It should be kept in its original packaging, protected from light, and must not be frozen or shaken. Prior to administration, allow the vial to reach room temperature if required, and inspect for particulate matter or discoloration before use.
How is Menquadfi administered?+
Menquadfi is given as a single intramuscular injection, usually into the deltoid muscle of the upper arm. The injection should be performed by a qualified healthcare professional using aseptic technique. The site may be observed for a short period after vaccination to monitor for immediate adverse reactions.
What are the most serious risks to watch for with Menquadfi?+
The most serious adverse events associated with Menquadfi are rare but include severe allergic reactions such as anaphylaxis, Guillain‑Barré syndrome, and neurologic events like seizures. Recipients should be observed for at least 15 minutes after injection, and any signs of severe hypersensitivity or neurological symptoms should prompt immediate medical evaluation.
Who should not receive Menquadfi?+
Menquadfi is contraindicated in individuals with a known hypersensitivity to tetanus toxoid, any component of the vaccine, or a previous severe allergic reaction to a meningococcal conjugate vaccine. Persons with acute moderate or severe illness should defer vaccination until recovery, and those with uncertain immune status should consult a healthcare professional before receiving the vaccine.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Neisseria Meningitidis, Serogroup C, Polysaccharide, Conjugated To Tetanus Toxoid, Neisseria Meningi
Route
Intramuscular Use
Manufacturer
Sanofi Winthrop Industrie
Origin
EU